Aethlon Medical, Inc. (AEMD): Price and Financial Metrics

Aethlon Medical, Inc. (AEMD): $5.20

-0.16 (-2.99%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AEMD ranks best; there it ranks ahead of 65.82% of US stocks.
  • AEMD's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • AEMD ranks lowest in Stability; there it ranks in the 7th percentile.

AEMD Stock Summary

  • The ratio of debt to operating expenses for Aethlon Medical Inc is higher than it is for about only 0.51% of US stocks.
  • AEMD's price/sales ratio is 80.77; that's higher than the P/S ratio of 96.08% of US stocks.
  • With a year-over-year growth in debt of -100%, Aethlon Medical Inc's debt growth rate surpasses just 0% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aethlon Medical Inc are HUSA, AMSC, PED, FI, and SNES.
  • AEMD's SEC filings can be seen here. And to visit Aethlon Medical Inc's official web site, go to

AEMD Price Target

For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

AEMD Stock Price Chart Interactive Chart >

Price chart for AEMD

AEMD Price/Volume Stats

Current price $5.20 52-week high $12.49
Prev. close $5.36 52-week low $1.22
Day low $5.05 Volume 549,298
Day high $5.35 Avg. volume 3,131,134
50-day MA $2.58 Dividend yield N/A
200-day MA $2.10 Market Cap 63.08M

Aethlon Medical, Inc. (AEMD) Company Bio

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.

AEMD Latest News Stream

Event/Time News Detail
Loading, please wait...

AEMD Latest Social Stream

Loading social stream, please wait...

View Full AEMD Social Stream

Latest AEMD News From Around the Web

Below are the latest news stories about Aethlon Medical Inc that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers

Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%, Fusion Pharmaceuticals (FUSN) -14%, Clearside Biomedical (CLSD) -11%, Aethlon Medical (AEMD) -8%....

Seeking Alpha | June 16, 2021

Is Aethlon Medical, Inc. (AEMD) A Good Stock To Buy?

No summary available.

Insider Monkey | June 15, 2021

GameStop investor argues why 'there is a fundamental backing to it'

Heriot-Watt University in Edinburgh, student Thushira Kumarage joins Yahoo Finance's Myles Udland, Julie Hyman and Brian Sozzi to discuss retail trading and meme stocks.

Yahoo | June 11, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Welcome back, investors!

William White on InvestorPlace | June 10, 2021

Why Aethlon Medical''s Stock Is Plunging Today

After surging 400% yesterday, Aethlon Medical, Inc. (NASDAQ: Full story available on

Benzinga | June 10, 2021

Read More 'AEMD' Stories Here

AEMD Price Returns

1-mo 205.88%
3-mo 141.86%
6-mo 151.21%
1-year 94.76%
3-year -72.70%
5-year -93.67%
YTD 110.53%
2020 156.49%
2019 -96.13%
2018 46.90%
2017 -73.10%
2016 -38.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1317 seconds.